JAMA
Original Investigation
April 6, 2024
Richard M.听Martin,听BM, BS, PhD; Emma L.听Turner,听PhD; Grace J.听Young,听MSc; Chris听Metcalfe,听PhD; Eleanor I.听Walsh,听MSc; J. Athene听Lane,听PhD; Jonathan A. C.听Sterne,听PhD; Sian听Noble,听PhD; Peter听Holding,听MSc; Yoav听Ben-Shlomo,听MBBS, PhD; Naomi J.听Williams,听PhD; Nora听Pashayan,听MD, PhD; Mai Ngoc听Bui,听PhD; Peter C.听Albertsen,听MD; Tyler M.听Seibert,听MD, PhD; Anthony L.听Zietman,听MD; Jon听Oxley,听MD; Jan听Adolfsson,听MD; Malcolm D.听Mason,听MD; George听Davey Smith,听DSc; David E.听Neal,听MD; Freddie C.听Hamdy,听MD; Jenny L.听Donovan,听PhD; CAP Trial Group
is active quiz
has multimedia
JAMA. 2024; 331(17):1460-1470. 10.1001/jama.2024.4011
This secondary analysis of a randomized clinical trial assesses whether screening for prostate-specific antigen reduces prostate cancer mortality at 15-year follow-up.
JAMA Cardiology
Original Investigation
January 16, 2019
John听Gregson,听PhD; Stephen听Kaptoge,听PhD; Thomas听Bolton,听MSc; Lisa听Pennells,听PhD; Peter听Willeit,听MD; Stephen听Burgess,听PhD; Steven听Bell,听PhD; Michael听Sweeting,听PhD; Eric B.听Rimm,听ScD; Christopher听Kabrhel,听MD; Bengt听Z枚ller,听MD; Gerd听Assmann,听MD; Vilmundur听Gudnason,听MD; Aaron R.听Folsom,听MD; Volker听Arndt,听MD; Astrid听Fletcher,听MD; Paul E.听Norman,听MD; B酶rge G.听Nordestgaard,听MD; Akihiko听Kitamura,听PhD; Bakhtawar K.听Mahmoodi,听MD; Peter H.听Whincup,听MD; Matthew听Knuiman,听PhD; Veikko听Salomaa,听MD; Christa听Meisinger,听MD; Wolfgang听Koenig,听MD; Maryam听Kavousi,听MD; Henry听V枚lzke,听MD; Jackie A.听Cooper,听MBBS; Toshiharu听Ninomiya,听PhD; Edoardo听Casiglia,听MD; Beatriz听Rodriguez,听MD; Yoav听Ben-Shlomo,听MD; Jean-Pierre听Despr茅s,听MD; Leon听Simons,听MD; Elizabeth听Barrett-Connor,听MD; Cecilia听Bj枚rkelund,听MD; Marlene听Notdurfter,听MD; Daan听Kromhout,听PhD; Jackie听Price,听MD; Susan E.听Sutherland,听PhD; Johan听Sundstr枚m,听MD; Jussi听Kauhanen,听MD; John听Gallacher,听PhD; Joline W. J.听Beulens,听PhD; Rachel听Dankner,听MD; Cyrus听Cooper,听FMedSci; Simona听Giampaoli,听MD; Jason F.听Deen,听MD; Agust铆n听G贸mez de la C谩mara,听MD; Lewis H.听Kuller,听PhD; Annika听Rosengren,听PhD; Peter J.听Svensson,听MD; Dorothea听Nagel,听PhD; Carlos J.听Crespo,听MD; Hermann听Brenner,听MD; Juan R.听Albertorio-Diaz,听MA; Robert听Atkins,听MBBS; Eric J.听Brunner,听PhD; Martin听Shipley,听MSc; Inger听Nj酶lstad,听MD; Deborah A.听Lawlor,听MSc; Yvonne T.听van der Schouw,听PhD; Randi Marie听Selmer,听PhD; Maurizio听Trevisan,听MD; W. M. Monique听Verschuren,听MD; Philip听Greenland,听MD; Sylvia听Wassertheil-Smoller,听PhD; Gordon D. O.听Lowe,听MD; Angela M.听Wood,听PhD; Adam S.听Butterworth,听PhD; Simon G.听Thompson,听PhD; John听Danesh,听FMedSci; Emanuele听Di Angelantonio,听FRCP; Tom听Meade,听FRS; for the Emerging Risk Factors Collaboration
open access
JAMA Cardiol. 2019; 4(2):163-173. 10.1001/jamacardio.2018.4537
This analysis of data from the Emerging Risk Factors Collaboration and the UK Biobank estimates the associations of major cardiovascular risk factors with venous thromboembolism.
JAMA
Original Investigation
March 6, 2018
Richard M.听Martin,听PhD; Jenny L.听Donovan,听PhD; Emma L.听Turner,听PhD; Chris听Metcalfe,听PhD; Grace J.听Young,听MSc; Eleanor I.听Walsh,听MSc; J. Athene听Lane,听PhD; Sian听Noble,听PhD; Steven E.听Oliver,听PhD; Simon听Evans,听MD; Jonathan A. C.听Sterne,听PhD; Peter听Holding,听MSc; Yoav听Ben-Shlomo,听PhD; Peter听Brindle,听MD; Naomi J.听Williams,听PhD; Elizabeth M.听Hill,听MSc; Siaw Yein听Ng,听PhD; Jessica听Toole,听MSc; Marta K.听Tazewell,听MSc; Laura J.听Hughes,听BA; Charlotte F.听Davies,听PhD; Joanna C.听Thorn,听PhD; Elizabeth听Down,听MSc; George听Davey Smith,听DSc; David E.听Neal,听MD; Freddie C.听Hamdy,听MD; CAP Trial Group
free access
JAMA. 2018; 319(9):883-895. 10.1001/jama.2018.0154
This cluster randomized trial evaluates the effect of a single prostate-specific antigen (PSA) screening test on 10-year prostate cancer鈥搒pecific mortality among men aged 50 to 69 years treated at UK primary care practices.